<DOC>
	<DOC>NCT03011281</DOC>
	<brief_summary>The objectives of this single center, prospective, non-interventional inception cohort is to understand patient characteristics, general treatment patterns, effectiveness, and safety of Tofacitinib for rheumatoid arthritis patients in the real-world setting. 1. To evaluate the baseline characteristics of Korean RA patients treated with Tofacitinib 2. To evaluate the effectiveness and safety of Tofacitinib in clinical practice in Korean RA patients. 3. To further evaluate safety, effectiveness and demographic characteristics of the patients treated with Tofacitinib matched with and compared to biologic DMARDs from the BIOPSY registry database.</brief_summary>
	<brief_title>Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>A. Patients who provide a written informed consent form of participating in this study. B. Patients who are more than 19 years old. C. Patients with moderately to severely active rheumatoid arthritis as defined per EULAR guidelines, who have had an inadequate response or are intolerant to methotrexate. A. Patients who do not provide a written informed consent form of participating in this study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>